Search Results

You searched for : Lynparza

	Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer ... Jun 24
	LYNPARZA (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Treatments in BRCA1/2-Mutated Advanced Prostate Cancer... Jun 24
	LYNPARZA (olaparib) Receives Three New Approvals in Japan LYNPARZA has been approved in Japan for the treatment of three types of advanced cancer: ovarian, prostate and pancreatic cancer.... Dec 28
	Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer Lynparza in combination with bevacizumab demonstrated as a treatment for the treatment of HRD-positive advanced Ovarian Cancer... Nov 05
	LYNPARZA Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Agent Treatments in BRCA1/2-Mutated mCRPC... Nov 05
	DCGI approves AstraZeneca Olaparib tablets for ovarian and breast cancer AstraZeneca's patented olaparib for ovary and breast cancer now in India... Aug 20
	Positive About COVID-19 Vaccine, Says UK Pharma Firm AstraZeneca has already reached deals with countries to make more than 2 billion doses of its COVID-19 vaccine with Oxford Univeristy ... Jul 31
	AstraZeneca-Merckâ€™s Lynparza wins EU approval for pancreatic cancer Pancreatic cancer is a rare, life-threatening disease with the lowest survival rate among the most common cancers. ... Jul 08
8 Matching result(s) found!

-Advertisements-

Trending Now
	EV Conference 24---Charging Up for e-mobility Minister Ponnam Prabhakar and Jayesh Ranjan among others to graceJune 14, 2024
	Are we on track to end AIDS, end viral hepatitis and end STIs by 2030?June 14, 2024
	HR Conclave Focusing on Future-Forward Engineering where Engineering and Management students meet their future employees, thus exposing students to real-world HR challenges and innovative solutionsJune 14, 2024
	MAGGI Empowers 10 Women to Bring their Entrepreneurial dreams to lifeJune 13, 2024
	FTCCI announced its Annual Excellence Awards and invites entries, last date is 20th June 2024June 13, 2024
	Bird Flu Cases by Dr Praveen Gupta, Principle Director and Chief of Neurology, Fortis Hospital.June 13, 2024
	Sova Health's $1 Million Seed Funding to Drive Gut Health InnovationJune 13, 2024
	The Vital Role of Early Detection: Kevin Jonas on Battling Skin CancerJune 13, 2024
	Zumutor Biologics Advances Cancer Care with Novel Immunotherapy ZM008: A First-in-Class Anti LLT1 AntibodyJune 13, 2024
	HP Ghosh Hospital Unveils Innovative "Chest Tree" June 12, 2024
	Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, IndiaJune 12, 2024
	From the frontlines: Homeless person won over alcoholism, survived floods and defeated TBJune 12, 2024
	The Role of Hormones in Obesity: Why Men and Women Gain Weight DifferentlyJune 12, 2024
	Silent Killer: How a Young Mother’s Vision Loss Led to a Lung Cancer DiagnosisJune 12, 2024
	TruAlt Bioenergy’s subsidiary, Leafiniti Bioenergy supplies over 1000 tons of Compressed Biogas to AG&P Pratham in just 5 monthsJune 11, 2024
	Southeast Asia's Most Advanced Luxury Postpartum Centre Re'Joy Suites Opens in SingaporeJune 11, 2024
	Poor Muscle Health in Obesity Can be A Major Risk Factor for Early DeathJune 11, 2024
	Machine Learning Uncovers How Organ Ageing Impacts Health and LongevityJune 11, 2024
	Why Education is Essential for Health and LongevityJune 11, 2024
	New Study Reveals Antidepressant Withdrawal Symptoms Less Common but Still SignificantJune 10, 2024

Search Results

Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

LYNPARZA (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

LYNPARZA (olaparib) Receives Three New Approvals in Japan

Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

LYNPARZA Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer

DCGI approves AstraZeneca Olaparib tablets for ovarian and breast cancer

Positive About COVID-19 Vaccine, Says UK Pharma Firm

AstraZeneca-Merckâ€™s Lynparza wins EU approval for pancreatic cancer

Trending Now